纵向人群队列中无痴呆人群淀粉样蛋白阳性的患病率与结局
该前瞻性人群队列研究纳入1671名无痴呆参与者,基于11C-匹兹堡化合物B PET定义淀粉样蛋白阳性(标准化摄取比值>1.42)。基线时无认知障碍者淀粉样蛋白阳性率随年龄从50-59岁的2.7%升至80-89岁的41.3%,淀粉样蛋白阳性且无认知障碍者进展为遗忘型轻度认知障碍的风险为阴性者的2.26倍。
要点
- 无痴呆人群中无认知障碍者淀粉样蛋白阳性率随年龄从50-59岁的2.7%升至80-89岁的41.3%。
- 淀粉样蛋白阳性且无认知障碍者发生遗忘型轻度认知障碍的风险为阴性者的2.26倍(HR,95%CI 1.52-3.35)。
- 淀粉样蛋白阳性者随访期间整体认知和记忆领域z评分显著下降。
核心结论
- 基于人群的淀粉样蛋白阳性患病率及阳性进展率可为设计阿尔茨海默病预防试验和评估预防干预的公共卫生结局提供有效信息。
研究设计与样本
- 前瞻性、基于人群的梅奥诊所衰老研究,对象为明尼苏达州奥姆斯特德县随机选取的无痴呆居民,2008年8月1日至2018年9月18日期间基线和每15个月进行临床和认知评估,并受邀接受碳11-匹兹堡化合物B正电子发射断层扫描(PET)成像。
- 3894名参与者中1671名接受PET成像并纳入研究,2198名未接受成像,25名因其他原因被排除;平均(SD)年龄71.3(9.8)岁,892名(53.4%)为男性,179名(10.7%)患有现患轻度认知障碍(MCI)。
- 淀粉样蛋白阳性定义为PET标准化摄取比值>1.42。
主要发现
- 基线时无痴呆人群中无认知障碍者淀粉样蛋白阳性率从50-59岁的2.7%(95%CI 0.5%-4.9%)升至80-89岁的41.3%(95%CI 33.4%-49.2%)。
- 无痴呆人群中淀粉样蛋白阳性MCI患病率从50-59岁的0%升至80-89岁的16.4%(95%CI 10.3%-22.5%)。
- 淀粉样蛋白阳性且无认知障碍者发生遗忘型MCI的风险为淀粉样蛋白阴性者的2.26倍(HR 2.26;95%CI 1.52-3.35;P<.001)。
- 淀粉样蛋白阳性MCI者进展为阿尔茨海默病痴呆的风险为淀粉样蛋白阴性MCI者的1.86倍(HR 1.86;95%CI 0.89-3.88;P=.10),未达统计学显著。
- 淀粉样蛋白阳性遗忘型MCI者进展为阿尔茨海默病痴呆的风险为淀粉样蛋白阴性遗忘型MCI者的1.63倍(HR 1.63;95%CI 0.78-3.41;P=.20),未达统计学显著;淀粉样蛋白阳性且无认知障碍或遗忘型MCI者进展为阿尔茨海默病痴呆的风险为淀粉样蛋白阴性者的2.56倍(HR 2.56;95%CI 1.35-4.88;P=.004)。
关键数值与推荐
- 淀粉样蛋白阳性定义:PET标准化摄取比值>1.42。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Brain amyloid deposition is a marker of Alzheimer disease (AD) pathology. The population-based prevalence and outcomes of amyloid positivity in a population without dementia are important for understanding the trajectory of amyloid positivity to clinically significant outcomes and for designing AD prevention trials. OBJECTIVE: To determine prevalence and outcomes of amyloid positivity in a population without dementia. DESIGN, SETTING, AND PARTICIPANTS: In the prospective, population-based Mayo Clinic Study of Aging in Olmsted County, Minnesota, participants without dementia were randomly selected from the county population and were clinically and cognitively evaluated at baseline and every 15 months from August 1, 2008, to September 18, 2018. They were also invited to undergo carbon11-Pittburgh compound B positron emission tomography (PET) imaging. EXPOSURES: Amyloid positivity (defined as a standardized uptake value ratio >1.42 on PET). MAIN OUTCOMES AND MEASURES: Prevalence of amyloid positivity in the Olmsted County population without dementia and risk of progression from no cognitive impairment (ie, normal cognition for age) to incident amnestic MCI (aMCI) and from MCI or aMCI to incident AD dementia. RESULTS: Of 3894 participants, 1671 underwent PET imaging and were included in the study; 2198 did not undergo imaging, and 25 were excluded for other reasons. The mean (SD) age of participants was 71.3 (9.8) years; 892 (53.4%) were men, and 179 (10.7%) had prevalent MCI. The prevalence of amyloid positivity without cognitive impairment in the population without dementia increased from 2.7% (95% CI, 0.5% to 4.9%) in persons aged 50 to 59 years to 41.3% (95% CI, 33.4% to 49.2%) in those aged 80 to 89 years at baseline. Prevalence of amyloid-positive MCI in the population without dementia increased from 0% in persons aged 50 to 59 years to 16.4% (95% CI, 10.3% to 22.5%) in those aged 80 to 89 years. The incident aMCI risk increased more than 2-fold in participants without cognitive impairment who were amyloid positive vs those who were amyloid negative (hazard ratio [HR], 2.26; 95% CI, 1.52 to 3.35; P < .001). The risk of AD dementia was 1.86 (95% CI, 0.89 to 3.88; P = .10) for amyloid-positive participants with MCI vs amyloid-negative participants with MCI, 1.63 (95% CI, 0.78 to 3.41; P = .20) for participants with aMCI who were amyloid positive vs amyloid negative, and 2.56 (95% CI, 1.35 to 4.88; P = .004) for amyloid-positive participants who were either without cognitive impairment or had aMCI vs those who were amyloid negative. Global cognitive and memory domain z scores declined significantly in amyloid-positive individuals during follow-up. The mean (SD) follow-up time from baseline was 3.7 (1.9) years to incident aMCI and 3.8 (2.0) years to incident AD dementia. CONCLUSIONS AND RELEVANCE: Population-based prevalence of amyloid-positive status and progression rates of amyloid positivity provide valid information for designing AD prevention trials and assessing the public health outcomes of AD prevention and interventions.
引用
- Roberts RO, Aakre JA, Kremers WK, et al. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting. JAMA Neurol. 2018. PMID: 29710225. doi:10.1001/jamaneurol.2018.0629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。